Evidence map›Paper›PMID 31434866›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

SUCO as a Promising Diagnostic Biomarker of Hepatocellular Carcinoma: Integrated Analysis and Experimental Validation.

Chaosen Yue, Chaojie Liang, Hua Ge, Lijun Yan, Yingchen Xu, Guangming Li, Jixiang Wu

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chaosen YueDepartment of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China (mainland).
Chaojie LiangDepartment of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China (mainland).
Hua GeDepartment of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China (mainland).
Lijun YanDepartment of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China (mainland).
Yingchen XuDepartment of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China (mainland).
Guangming LiDepartment of General Surgery, Beijing Tongren Hospital, Capital Medical University,, Beijing, China (mainland).
Jixiang WuDepartment of General Surgery, Beijing Tongren Hospital, Capital Medical University,, Beijing, China (mainland).
Capital Medical University · CNBeijing Tongren Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Hepatocellular carcinoma (HCC) is not frequently diagnosed until the late stage due to its concealed symptoms. Therefore, the identification of biomarkers that have effective diagnostic performance and act as potential key therapeutic targets for HCC becomes urgent. MATERIAL AND METHODS Comprehensive analysis of accumulated data downloaded from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) databases was used to obtain more reliable potential diagnostic biomarkers of HCC and to explore related molecular mechanisms. Meta-analysis and summary receiver operating characteristic (SROC) curve analysis were performed to evaluate the differential expression of SUCO gene in HCC and identify the capability of SUCO in distinguishing HCC-tissues from normal liver-tissues. RESULTS SUCO was found to be upregulated in HCC-tissues and exhibited a favorable value in diagnosing HCC. Bioinformatics analysis showed that SUCO might play important roles in HCC progression, and was significantly related to cell cycle, cell metabolism, and proliferation. CONCLUSIONS This study was the first to demonstrate that SUCO was overexpressed in HCC-tissues, and that high expression of SUCO was significantly related to poor overall survival in HCC patients. SUCO might be a potential diagnostic biomarker for HCC patients, which promotes the tumorigenesis and progression of HCC.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularCell Transformation, NeoplasticComputational BiologyDatabases, GeneticDisease ProgressionGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMembrane ProteinsMicroRNAsROC CurveBiomarkers, TumorMembrane ProteinsMicroRNAsSUCO protein, human

Identifiers

PMID31434866
PMCPMC6716297
OpenAlexW2969648312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.